---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076833"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:45:12.329259+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M

## Summary
- Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026
- Net loss for FY2025 was $8.9 million ($23.95 per share) vs $15.0 million ($1,052.16 per share) in FY2024
- Announced positive results from PRIME clinical study in late-stage chronic kidney disease patients
- Reached agreement with FDA on a single adaptive Phase 2/3 study for Gemini to treat acute kidney injury
- Clinical data on Gemini for AKI and CKD to be presented at International Conference on Advances in Critical Care Nephrology (March 29-April 1, 2026)

## SEC filing metadata
- accession: 0001193125-26-076833
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000119312526076833/0001193125-26-076833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000119312526076833/revb-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076833
- JSON: https://secwatch.observer/filing/0001193125-26-076833.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.